Drugs / Nelmastobart
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07656038 | Jun 2026 → Jul 2028 expected | colorectal cancer | STCube, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05231746 | Apr 2022 → Feb 2024 | neoplasm | STCube, Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06873763 | Jun → Dec 2025 overdue | colorectal cancer | STCube, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06016270 | Feb 2024 → Jan 2025 | small cell lung carcinoma | STCube, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT05990543 | Jan 2024 → Dec 2025 overdue | colorectal cancer | Korea University Anam Hospital | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07306624 | Jan 2026 → Aug 2027 expected | non-small cell lung carcinoma | STCube, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nelmastobart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07306624 ↗ |
| Known as | hSTC810 | “Nelmastobart（hSTC810） is a novel humanized monoclonal antibody” NCT07656038 ↗ |
| Modality | Monoclonal antibody | “novel humanized monoclonal antibody” NCT07656038 ↗ |
| Route | Intravenous | “administered as an intravenous infusion (IV)” NCT05231746 ↗ |
| Target | BTN1A1 | “targets a novel immune checkpoint protein, BTN1A1+” NCT07656038 ↗ |